CNS Pharmaceuticals, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
CNS Pharmaceuticals, Inc. (CNSP) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $1.03 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $1.03M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $999.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $873.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $715.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2025-12-31 | $1.03M 10-K · filed 2026-03-31 |
| 2024-12-31 | $999.00K 10-K · filed 2026-03-31 |
| 2023-12-31 | $873.00K 10-K · filed 2025-03-31 |
| 2022-12-31 | $715.00K 10-K · filed 2024-04-01 |
| 2021-12-31 | $533.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |